Sponsored by
All new trials should consider adding an Optune arm. Currently, a few interesting trials are not allowing patients to use Optune at the same time as the trial. I feel that is not ethical. Optune has been shown to more than double the 5 year survival rate for adult GBM. If you have to make a choice between trying Optune with a proven benefit and minimal side effects to trying an experimental therapy with no track record and inknown side effects, I would choose Optune. [Disclaimer: Novocure is a sponsor of the Musella Foundation]